KRAS and pancreatic neoplasm: Whereas inhibition of the MAPK pathway by the MEK1/2 inhibitor U0126 decreases Gli1 stability and suppresses the Gli1-mediated transcriptional activity in a KRAS-mutated pancreatic cancer cell line.